Aristotle Atlantic Partners LLC Invests $2.73 Million in Immunome, Inc. $IMNM

Aristotle Atlantic Partners LLC acquired a new stake in shares of Immunome, Inc. (NASDAQ:IMNM) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 125,018 shares of the company’s stock, valued at approximately $2,734,000.

A number of other institutional investors have also recently made changes to their positions in the business. KBC Group NV acquired a new stake in shares of Immunome in the 1st quarter worth $60,000. Strs Ohio acquired a new stake in Immunome in the fourth quarter worth about $64,000. Assetmark Inc. boosted its holdings in Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after acquiring an additional 1,442 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Immunome during the fourth quarter worth about $121,000. Finally, BNP Paribas Financial Markets grew its stake in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IMNM. Leerink Partners cut their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. HC Wainwright reiterated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, Truist Financial raised their price target on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

Immunome Stock Up 0.9%

Shares of NASDAQ:IMNM opened at $22.21 on Friday. Immunome, Inc. has a 52-week low of $8.66 and a 52-week high of $27.65. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of -9.33 and a beta of 2.07. The business has a 50-day moving average price of $21.02 and a 200-day moving average price of $21.94.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. As a group, equities analysts anticipate that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Insider Activity at Immunome

In other news, CFO Max Rosett sold 60,000 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $18.23, for a total value of $1,093,800.00. Following the sale, the chief financial officer owned 54,037 shares in the company, valued at $985,094.51. This represents a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 101,050 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00. Following the completion of the sale, the director owned 308,504 shares in the company, valued at $6,515,604.48. The trade was a 24.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 472,142 shares of company stock worth $10,262,648 in the last ninety days. 7.21% of the stock is owned by company insiders.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.